Dr. Daniel Harki is an Associate Professor of Medicinal Chemistry, a Graduate Faculty member in the Department of Biochemistry, Molecular Biology, and Biophysics, a Faculty Member of the Stem Cell Institute, and a Member of the Masonic Cancer Center at the University of Minnesota-Twin Cities. Dr. Harki is also a co-Founder of ApoGen Biotechnologies, Inc.
Dr. Harki received his early training at West Virginia University, graduating with a B.A. in biology and chemistry in 1999. At WVU, Dr. Harki performed undergraduate research in the laboratory of Professor Kay Brummond on the synthesis of acylfulvene analogues, while concurrently working as a technician in the immunotoxicology laboratory of Dr. Michael Luster at the National Institute for Occupational Safety & Health in Morgantown, WV. In fall 1999, Dr. Harki began graduate studies in chemistry at The Pennsylvania State University working on the development of synthetic, antiviral nucleosides in the laboratory of Professor Blake Peterson. In 2005, Dr. Harki earned his Ph.D. in Chemistry from Penn State and subsequently began postdoctoral studies at the California Institute of Technology under the direction of Professor Peter Dervan. While at Caltech (2005-2009), Dr. Harki worked on projects that focused on the solution-phase synthesis and in vivo imaging of DNA-binding pyrrole-imidazole polyamides. In 2009, Dr. Harki began his independent academic career at the University of Minnesota.
The Harki laboratory is focused on the discovery and development of small molecule probes and therapeutics for APOBEC3 enzymes and transcription factors, such as NF-κB and androgen receptor. Chemical probes that exert their effects through a covalent mechanism of inhibition are of particular interest.